Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 123, Issue 3, Pages 798-806Publisher
WILEY
DOI: 10.1002/jso.26416
Keywords
cancer; immunotherapy; solid tumors; tumor immunology
Funding
- NCATS NIH HHS [UL1 TR002378, TL1 TR002382] Funding Source: Medline
- NCI NIH HHS [F30 CA243307] Funding Source: Medline
Ask authors/readers for more resources
This article discusses the importance of immunotherapy in cancer treatment and presents successful cases of PD-1 and CTLA-4 blockade therapy, as well as biomarkers of therapeutic response. Additionally, it also examines novel targets in Phase III clinical trials and innovations aimed at improving outcomes in therapy-resistant solid tumors.
While surgical resection, local and cytotoxic therapies have long formed the basis of cancer care, immunotherapy now plays a key role in supplementing and even replacing these agents in the first line. Here we review the early success of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 blockade and discuss biomarkers of therapeutic response. We next highlight a select group of novel targets in Phase III trials both as monotherapies and in combination with PD-1 inhibitors. Finally, we discuss innovations which seek to improve outcomes in therapy-resistant solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available